Concepedia

Leonid Dubrovsky

LD

13

Publications

2.5K

Citations

13

H-Index

2004

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Eisai (United States)

Icahn School of Medicine at Mount Sinai

Kindai University

University of California, Los Angeles

Leonid Dubrovsky is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, radiation oncology, and oncology.

ORCID

Top concepts

Publications per year

2004–2025

13

Publications

13

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu et al. · Journal of Clinical Oncology · 2020 · 1.1K citations · Full text

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 364 citations

, , +10

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

Masatoshi Kudo, Zhenggang Ren, Yabing Guo et al. · The Lancet · 2025 · 161 citations

, , +8

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1

Tao Dao, Dmitry Pankov, Andrew Scott et al. · Nature Biotechnology · 2015 · 156 citations · Full text

, , +8

Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.

Josep M. Llovet, Masatoshi Kudo, Ann‐Lii Cheng et al. · Journal of Clinical Oncology · 2019 · 109 citations

, , +21

Rows per page

1–5 of 13